Type I interferon response plays a prominent role against viral infection, which is frequently 14 disrupted by viruses. Here, we report Bcl-2 associated transcription factor 1 (Bclaf1) is 15 degraded during the alphaherpesvirus Pseudorabies virus (PRV) and Herpes simplex virus 16 type 1 (HSV-1) infections through the viral protein US3. We further reveal that Bclaf1 functions 17 critically in type I interferon signaling. Knockdown or knockout of Bclaf1 in cells significantly 18 impairs interferon-α (IFNα) -mediated gene transcription and viral inhibition against US3 19 deficient PRV and HSV-1. Mechanistically, Bclaf1 maintains a mechanism allowing STAT1 and 20 STAT2 to be efficiently phosphorylated in response to IFNα, and more importantly, facilitates 21 IFN-stimulated gene factor 3 (ISGF3) binding with IFN-stimulated response elements (ISRE) 22 for efficient gene transcription by directly interacting with ISRE and STAT2. Our studies 23 establish the importance of Bclaf1 in IFNα-induced antiviral immunity and in the control of viral 24 infections. 25 26
Introduction 27 28
Herpesviridae is a family of large DNA viruses with an ability to establish persistent infection in 29
hosts. The viruses have evolved multiple strategies to establish persistent infection and 30 combat host defenses; among these, the interferon (IFN) antiviral response is most prominent. 31
Members of the family are causative agents of a variety of human and animal diseases and 32 are further grouped into the three subfamilies, including alpha-, beta-and 33 gammaherpesviruses (Steiner & Benninger, 2013) . The alphaherpesvirus subfamily is 34 neurotropic, including the genera simplexvirus and varicellovirus. 35
Pseudorabies virus (PRV) and herpes simplex virus type 1 (HSV-1) belong to the 36 alphaherpesvirus subfamily and the genera varicellovirus and simplexvirus, respectively. They 37 are often used as model viruses to study alphaherpesvirus biology. PRV is a swine pathogen 38 that causes the economically important Aujeszky's disease (Muller, Hahn et al., 2011, 39 Pomeranz, Reynolds et al., 2005) . HSV-1 is a human restricted virus, resulting in various 40 mucocutaneous diseases, such as herpes labialis, genital herpes, herpetic whitlow, and 41 keratitis (Roizman & Whitley, 2013) . It also causes serious encephalitis in a small portion of the 42 infected individuals (Roizman & Whitley, 2013) . 43 Viral infection is defended by hosts at multiple levels, including intrinsic, innate and adaptive 44 immunity. The type I Interferon (IFN-I) response plays a central role in innate immunity against 45 viral infection. IFN-I positions cells in a potent antiviral state by inducing the synthesis of 46 hundreds of antiviral proteins encoded by IFN-stimulated genes (ISGs). This process is 47 initiated by binding of IFN-I to its receptor subunits (IFNAR1 and IFNAR2), which leads to the 48 activation of the Janus Kinases (JAKs), JAK1 and TYK2. Activated JAKs then phosphorylate 49 signal transducer and activator of transcription (STAT) 1 and 2, leading to the formation of a 50 trimeric complex, referred to as IFN-stimulated gene factor 3 (ISGF3), which is comprised of 51 STAT1/STAT2 and IFN regulatory factor 9 (IRF9). ISGF3 translocates to the nucleus and binds 52
to IFN-stimulated response elements (ISRE) in the DNA to initiate the transcription of ISGs 53 (Platanias, 2005 , Stark & Darnell, 2012 . Many of the gene products various strategies to antagonize the functions of IFN, which might be particularly important for 56 herpesviruses to establish persistent infection in hosts (Garcia-Sastre, 2017, Katze, He et al., 57 2002, Schulz & Mossman, 2016) . Key molecules in IFN signaling are targeted by various 58 components of alphaherpesviruses. For example, PRV or HSV-1 utilize their encoded 59 dUTPase UL50 to induce IFNAR1 degradation and inhibit type I IFN signaling in an enzymatic 60 activity-independent manner (Zhang, Xu et al., 2017) . 61
Increasing evidence indicates that IFN signaling is subject to extensive regulation and that 62 additional coregulators are required to modulate the transcription of ISGs. For instance, the 63 methyltransferase SETD2 promotes IFNα-dependent antiviral immunity via catalyzing STAT1 64 methylation on K525 ( Bclaf1 (Bcl-2 associated transcription factor 1; also called Btf for Bcl-2 associated 84 transcription factor) was initially identified in a yeast two-hybrid system as a binding protein for 85 adenovirus E1B 19K protein (Kasof, Goyal et al., 1999) . It contains homology to the basic 86 zipper (bZip) and Myb domains and binds DNA in vitro (Kasof et al., 1999 utilized by the members of beta-and gammaherpesviruses to suppress the expression of Bclaf1 indicates that this protein has a very important antiviral function. However, whether 100
Bclaf1 is also involved in alphaherpesvirus infection and the molecular mechanism of its 101 antiviral function are not known. 102
In this study, we examined the role of Bclaf1 in alphaherpesvirus infection and found that 103 Bclaf1 is also degraded during PRV and HSV-1 infection through US3. More importantly, we 104 revealed Bclaf1 as a critical regulator in the IFN-induced antiviral response. On the one hand, 105
Bclaf1 maintains a mechanism that allows STAT1/STAT2 to be efficiently phosphorylated in 106 response to IFN; on the other hand, it interacts with ISGF3 complex in the nucleus mainly 107 through STAT2 and facilitates their interactions with the promoters of ISGs. These results 108 reveal a critical role for Bclaf1 in IFN signaling and a strategy employed by alphaherpesvirus to 109 disable it. 110 111
Results

113
PRV and HSV-1 dispatch US3 to degrade Bclaf1 in a proteasome-dependent manner 114 115
To examine the effect of alphaherpesvirus infection on Bclaf1, we infected porcine cells with 116 PRV and human cells with HSV-1. We observed a dramatic decrease in Bclaf1 levels in all the 117 cells examined at the time points when substantial viral proteins were expressed, including 118 porcine kidney PK15 ( Figure 1A To determine the viral protein responsible for the Bclaf1 degradation, we utilized a panel of 127 gene deletion PRVs, particularly EP0, US3 and UL50 deleted strains, since these viral proteins 128 are involved in the degradation of various proteins (Boutell & Everett, 2013 , Jung et al., 2011 , 129 Zhang et al., 2017 . Infecting cells with WT and the gene deletion PRVs showed that only the 130 PRV ∆US3 strain lost the ability to degrade Bclaf1 ( Figure 1E ). Indeed, although the Bclaf1 131 levels in the cells infected with PRV WT decreased over time up to 24 h post infection, those in 132 the PRV ∆US3 infected cells remained unchanged in the PK15 cells ( Figure 1F ) and even 133 increased in the ST cells ( Figure S1B , S1C and S1D). Similarly, the deletion of US3 from 134 HSV-1 also abolished its ability to decrease Bclaf1 in the HEp-2 cells ( Figure 1G ). Collectively, 135
these data indicate that US3 is essential for PRV-and HSV-1-induced Bclaf1 down-regulation. 136
It also suggests that certain cells may respond to PRV and HSV-1 infection by increasing 137
Bclaf1, which is concealed by US3 mediated Bclaf1 down-regulation. 138
To determine if US3 alone is sufficient to induce Bclaf1 degradation, we ectopically expressed 139 PRV or HSV-1 US3 in HEK293T cells. The expression of US3 but not the empty vector or 140 UL50 markedly reduced endogenous Bclaf1 ( Figure S1E ), which was rescued by MG132 141 treatment ( Figure 1H ). These results suggest that US3 induces the proteasomal degradation
Bclaf1 promotes the IFNα-mediated inhibition of PRV/HSV-1 replication 145 146
The degradation of Bclaf1 upon PRV/HSV-1 infection by US3 suggests that Bclaf1 may 147 possess an important antiviral function, which is inhibited by US3 but should be in action 148 against US3 deficient viruses. Thus, to determine the role of Bclaf1 in viral infection, we 149 focused on the differential properties between WT and ∆US3 PRV infected cells. Although one 150 well-known function of US3 is antiapoptosis, and Bclaf1 has been shown to be involved in it, 151
we observed a similar level of apoptosis induced by ∆US3 PRV infection in the Bclaf1 152 knockdown and control cells ( Figure S2 ). 153
The dramatic difference we observed between the WT and ∆US3 PRV/HSV1 was that the 154 latter was more susceptible to interferon. The deletion of US3 in PRV/HSV-1 significantly 155 decreased viral productions in PK15 (PRV) and HEp-2 (HSV-1) cells treated with IFNα, while 156 having no or a slight influence on viral growth in the absence of interferon treatment (Figure 2A To understand the exact role of Bclaf1 in the IFN signaling, we analyzed the signaling events 180 that might be impaired in Bclaf1-deficient cells. We observed reduced courses of 181 phosphorylation for STAT1 and STAT2 in response to IFNα in Bclaf1-KO HeLa cells ( Figure 4A In addition, our Chromatin Immunoprecipitation (ChIP) assays showed that IFNα-induced 195 binding of STAT1/STAT2 to the promoters of ISGs was also greatly decreased in HeLa cells ( Figure 5A ) and Bclaf1-silenced HEp-2 cells ( Figure S5 ) compared with that in 197 relative control cells. 198
Because Bclaf1 predominantly localized in the nucleus, we reasoned that Bclaf1 should exert 199 its function in the nucleus and that the reduced STAT1/STAT2 phosphorylation by IFNα upon 200
Bclaf1 reduction could be an indirect consequence. Therefore, we focused on the aspect that 201
Bclaf1 may enhance the binding of ISGF3 to the promoters. To exclude the possibility that the 202 impaired binding between STAT1/STAT2 to the ISGs promoters in the Bclaf1-knockdown cells 203 was due to the reduced nuclear STAT1/STAT2 in these cells, we performed a DNA pull-down 204 assay to directly measure whether STAT1/STAT2/IRF9 binding to the promoters was 205 enhanced by Bclaf1. An ISRE DNA was synthesized, biotin-labeled, and added into equal 206 amounts of purified STAT1/STAT2/IRF9 as well as increased concentrations of purified Bclaf1 207 followed by a streptavidin-bead pull-down. The addition of Bclaf1 drastically increased the 208 binding of STAT1/STAT2/IRF9 to Bio-ISRE in a dose-dependent manner, and Bclaf1 was 209 present in the Bio-ISRE pull-down complex ( Figure 5B ). Purified Bclaf1 was pulled down by 210
Bio-ISRE but not by Bio-GFP ( Figure 5C ), suggesting that Bclaf1 was directly bound to ISRE 211 specifically. The ChIP assay confirmed that Bclaf1 was bound to the promoter regions of ISGs 212
in HeLa cells ( Figure 5D ), which appeared to be constitutive and was not induced by IFNα 213 treatment. To further characterize the DNA sequence required for binding with Bclaf1, we 214 replaced entire ISRE consensus sequence (Mut1) or the core sequence of 5'-TTCNNTTT-3' 215 (Au-Yeung, Mandhana et al., 2013) (Mut2) with a sequence from GFP. We also mutated the 216 TTT motif near the 3' end of the ISRE by chancing TTT to TAT (Mut3). DNA pull-down assays 217 demonstrated that Mut1 and Mut2 failed to interact with Bclaf1, whereas Mut3 still could 218 ( Figure 5E ), indicating Bclaf1 binds with the core sequence of ISRE and the TTT motif is not 219 required. In aggregate, these data demonstrated that Bclaf1 bound with ISRE specifically and 220 promoted the association of ISGF3 with DNA. 221 222
Bclaf1 associates with ISGF3 223 224
To understand the molecular mechanism by which Bclaf1 facilitates ISGF3 binding to ISGs 225 promoters, we performed co-IP assays to examine the interaction between Bclaf1 and ISGF3, 226 which is composed of STAT1, STAT2 and IRF9. We constructed a HEp-2 cell line that 227 endogenously expresses Flag-Bclaf1 by adding a Flag to the Bclaf1 gene using the 228 CRISPR/Cas9 technique and is referred as HEp-2-Flag-Bclaf1. Fractionation of the cells 229 followed by co-IPs using a Flag-antibody showed that Flag-Bclaf1 interacted with STAT1, endogenous Bclaf1 was also detected in the immuno-complexes of STAT1, STAT2 or IRF9 232 after IPs of nuclear extracts of HeLa cells using their respective antibodies ( Figure S6 ). The 233 interaction between Bclaf1 and STAT1/STAT2/IRF9 occurred in the absence of IFNα treatment 234 and was increased after IFNα treatment, correlating with more STAT1/STAT2/IRF9 being 235 translocated into the nucleus ( Figure 6A , 6B and Figure S6 ). We further determined the 236 regions in Bclaf1 that mediated its association with STAT1, STAT2 or IRF9 by co-expressing 237 various Flag tagged Bclaf1 fragments with Ha tagged STAT1, STAT2 or IRF9 in HEK293T cells 238 and performing co-IPs, and identified the region 236-620 responsible for binding to these 239 proteins ( Figure 6C ). To examine whether the interaction between Bclaf1 and 240 STAT1/STAT2/IRF9 is required for its ability to enhance IFNα transcription, we overexpressed 241
Bclaf1 full-length and the indicated fragments in HEp-2 followed by IFNα treatment. mRNA 242 measurements showed that the IFNα-induced IFIT1 transcription was enhanced by full-length 243
Bclaf1 and Bclaf1-F2 (236-620), and not by the fragments that failed to bind with 244 STAT1/STAT2/IRF9 ( Figure 6D ). Taken together, these results suggest that Bclaf1 interacts 245 with ISGF3 complex in the nucleus, which is important for Bclaf1 to enhance the activation of 246 ISRE after IFNα stimulation. 247 248
Bclaf1 associates with ISGF3 complex primarily through interacting with STAT2 249 250
Next, we set out to determine how Bclaf1 interacts with ISGF3. We first examined the direct 251 interactions between Bclaf1 and the components of ISGF3 by mixing bacterially purified 252
His-STAT1, -STAT2 or -IRF9 with GST-Bclaf1 F2 followed by GST pull-down assays. Western 253 analysis showed that only His-STAT2 was able to be pulled down specifically by GST-Bclaf1 254 F2, whereas the other two were not ( Figure 7A and data not shown). These results hinted that 255 STAT2 is the crucial component connecting ISGF3 to Bclaf1. In supporting this, co-IP assays 256 showed that the interaction between Bclaf1 and STAT1 or IRF9 was enhanced by STAT2, and 257 not by IRF9 or STAT1 upon overexpression in 293T cells ( Figure 7B and 7C) . Moreover, the 258 interaction between Bclaf1 and STAT1 or IRF9 at endogenous levels was decreased upon 259 STAT2 knockdown in HEp-2-Flag-Bclaf1 cells treated with IFN ( Figure 7D ). In addition, in 260 vitro DNA pulldown assays demonstrated that in the absence of STAT2 Bclaf1 lost its ability to 261 recruit the components of ISGF3 to ISRE ( Figure 7E ). Collectively, these data indicate that 262 STAT2 is the key component mediating the binding of Bclaf1 to ISGF3 complex. 263 264
Discussion
266
The IFN response is critical in the control of viral infection and is often evaded or antagonized 267 by various viruses. Most identified strategies used by viruses to evade ISG expression 268 emphasize on the known signaling molecules in the IFN pathway targeted by various viral 269 components. Here, we revealed a novel positive regulator, Bclaf1, in IFN signaling and its 270 degradation by the viral protein US3 during alphaherpesvirus PRV and HSV-1 infection. 271
The evidence supporting Bclaf1 as a critical regulator in IFN-mediated antiviral response 272 includes the following: 1) IFNα-induced ISG transcription is greatly compromised in Bclaf1 273 knockdown or knockout cells; 2) Bclaf1 is required for the efficient phosphorylation of STAT1 complex to promoters of the ISGs; 4) Bclaf1 interacts with ISGF3 through STAT2; 5) Bclaf1 is 276 degraded by US3 during PRV and HSV-1 infection; and 6) In the absence of US3, PRV and 277 HSV-1 become more sensitive to IFNα treatment, which is partly due to the unreduced level of 278 Bclaf1 in the cells. These findings establish Bclaf1 as a critical positive regulator in IFN 279 signaling and indicate its importance in host innate immunity against herpesvirus infection, 280 which may be more broadly against other viruses as well. 281
We demonstrated that Bclaf1 was involved in two critical steps in IFN signaling, including the 282 efficient phosphorylation of STAT1 and STAT2 and binding of the transcriptional complex to 283 ISGs promoters (Figure 8) . At present, the mechanism by which Bclaf1 regulates 284 STAT1/STAT2 phosphorylation is unknown. STAT1/STAT2 phosphorylation is catalyzed by 285 JAK1 and TYK2 activated by IFN-induced receptor dimerization, which occurs rapidly in the 286 membrane. The mechanism for Bclaf1 to influence this step is likely indirect as Bclaf1 primarily 287 localized in the nucleus. Emerging evidence indicates that the modification states of these 288 components, prior to IFN engagement, also affect STAT1 and STAT2 phosphorylation by JAKs 289 Bclaf1 constitutively bound to the promoter of the ISGs without being enhanced by IFNα. It 304 also interacted with ISGF3 in the nucleus, which was not regulated by IFNα-induced 305 STAT1/STAT2 phosphorylation. However, as more and more STAT1/STAT2/IRF9 entered the 306 nucleus following the IFNα treatment, more STAT1/STAT2/IRF9 was found to bind to Bclaf1 307 and the promoter of the ISGs as well. Thus, one conceivable role of Bclaf1 in ISGF3 mediated 308 transcription is acting as a mediator attracting ISGF3 to its prebound ISGs promoters for 309 efficient transcription. A similar mode of action is also observed in Bclaf1-regulated C/EBPβ 310 transcription (Shao et al., 2016 ). Bclaf1 has a DNA-binding ability (Kasof et al., 1999) , and we 311 found that the binding between Bclaf1 and the promoter of the ISGs was likely to be a direct 312 event. It would be interesting to further elucidate how Bclaf1 interacts with the promoter of the 313
ISGs. 314
US3 is a potent alphaherpesviral kinase involved in antagonizing a wide range of host 315 antiviral mechanisms. Here, we uncovered a strategy for US3 to impair IFN-mediated antiviral 316 activity, which is to degrade Bclaf1. Bclaf1 was degraded by both genera of alphaherpeviruses 317 and was also inhibited by members of beta-and gammaherpesviruses, indicating that the feature of herpesviruses is the establishment of a persistent infection and reactivation upon 320 stress, Bclaf1 may participate in these processes. To establish persistent infection, 321 herpesviruses employ multiple strategies to counteract the antiviral activity of IFN (Paladino & were purchased from Sigma. Human IFNα was purchased from PEPROTECH (300-02AA). 337
Glutathione agarose was purchased from GE Healthcare (17-0756-01). Porcine IFNα was 338 described previously . Biotin 3' End DNA Labeling Kit was purchased 339 from Thermo Scientific (89818). 340
The following antibodies were used for co-Immunoprecipitation (co-IP): anti-Bclaf1 (1:100, 
Cell and viruses
HEK293T cells (human embryonic kidney, ATCC #CRL-3216), HeLa cells (ATCC #CCL-2), 364
HEp-2 cells (a kind gift from Dr. Xiaojia Wang which was described previously (Wang, 365 Patenode et al., 2011)), PK15 cells (ATCC #CCL-33), ST cells (swine testis, ATCC 366 #CRL-1746), and Vero cells (ATCC #CCL-81) were cultured in medium supplemented with 10% 367
(v/v) FBS at 37°C and 5% CO2. The PRV Bartha-K61, recombinant PRV UL50-knockout virus 368 (PRV ∆UL50), PRV EP0-knockout virus (PRV ∆EP0) and KOS strain of HSV-1 were described 369 previously (Han et al., 2012 , Xu et al., 2015 . The recombinant PRV US3-knockout virus (PRV 370 ∆US3) and the HSV-1 US3-knockout virus (HSV-1 ∆US3) were generated in this paper (see 371 below). 372 373
Plasmids
375
The PRV US3 gene was amplified from the Bartha-K61 genome, and the HSV-1 US3 gene 376 was amplified from the KOS genome. Both PRV and HSV-1 US3 were cloned into the pRK5 377 PRV ∆US3 was generated according to methods described previously (Xu et al., 2015) . Briefly, 427 PK15 cells were cotransfected with the viral genome and the CRISPR/Cas9 system containing 428 two targeting sgRNAs for US3. After PRV-mediated CPE was prominently observed, the 429 supernatants were collected, and the plaque assay was performed for subcloning the viruses. 430
Single colonies were determined via sequencing and a Western blot with PRV US3 antibodies. 431
For generation of HSV-1 ∆US3, HEK293T cells were transfected using the CRISPR/Cas9 432 system containing the targeting sgRNA for US3, and 24 h later, the cells were infected with 433 HSV-1 (KOS) at an MOI of 1. Viruses in the supernatants were collected at 48 h post infection 434 and was subcloned via plaque assays. Single colonies were determined via sequencing and a 435
Western blot with HSV-1 US3 antibodies. 436
Oligonucleotides used in this study are listed in Supplementary Table 1 . 437 438
Generation of Bclaf1-KO Cells 439 440
HeLa cells were seeded into a 6-well dish to achieve 70% confluency and were transfected 441 with CRISPR/Cas9 plasmids containing a target sequence complimentary to the fourth exon of 442 Bclaf1, and 48 h later, the cells were diluted and seeded into a 96-well dish at 0.5 cell/well in 443 complete DMEM media. Wells that contained a single colony were expanded until enough 444 cells were available for total protein extraction and determining Bclaf1 via a Western blot. 445
Oligonucleotides used in this study are listed in Supplementary Table 1 . 446 447
Generation of a HEp-2 cell line that endogenously expresses Flag-Bclaf1 448 449
To add a Flag tag to the endogenous Bclaf1, HEp-2 cells were seeded into a 6-well dish to target sequence complimentary to the intron that was prior to the ATG of Bclaf1 plus a donor 452 plasmid containing homologous arms and Puro-P2A-3×Flag sequences. After 48 h, medium 453 containing 2.5 mg/ml puromycin was added to select for tagged cells, and 48 h later, the cells 454 were diluted and seeded into a 96-well dish at 0.5 cell/well in complete DMEM media. Wells 455 that contained a single colony were expanded until enough cells were available for total protein 456 extraction and determining Flag-Bclaf1 via a Western blot. 457
Oligonucleotides used in this study are listed in Supplementary Table 1 . The ChIP assay was performed using a ChIP-IT Express enzymatic system (Active Motif, 469
Carlsbad, CA, USA) following the manufacturer's instructions. Briefly, cells were crosslinked 470 with 1% formaldehyde and neutralized with 0.125 M glycine. Purified chromatin was digested 471 to ~ 500 bp by enzymatic shearing. Anti-Bclaf1, anti-STAT1, anti-STAT2 or control IgG 472 antibodies were used for immunoprecipitation. After reverse crosslinking, the DNA samples 473 were analyzed by PCR followed by 3% agarose gel electrophoresis. Specific primers used are 474 listed in Supplementary Table 1 . 475 476
DNA Pulldown assay 477 478
Flag-STAT1, Flag-STAT2, Flag-IRF9 and Flag-Bclaf1 were purified from overexpressed 479 HEK293T cells stimulated with (STAT1/STAT2/IRF9) or without (Bclaf1) IFNα by 480 immunoprecipitation using M2 beads (Sigma). The biotinylated ISRE 481 (5'-GAGACTCAGTAGTTTCACTTTCCATCGTCCAGT-3') DNA oligos were synthesized by a 482
Biotin 3´ End DNA Labeling Kit (Thermo Scientific) and were then annealed and incubated with 483 the purified indicated Flag-tagged proteins for 30 min in binding buffer (10 mM Tris, 1 mM KCl, 484 1%NP-40, 1 mM EDTA, 5% glycerol) at room temperature. Then, streptavidin beads (Cell 485 Signaling) were added for incubation at 4°C for 1 h. After three washes with binding buffer, the 486 ISRE-binding proteins were eluted by boiling and analyzed by immunoblotting. 487 488
GST Pulldown 489 490
Purified His-STAT1/STAT2/IRF9 protein was incubated with GST-tagged Bclaf1 truncated 491 proteins or GST control protein in PBS buffer with glutathione agarose (GE Healthcare) for 1 h 492 at 4 °C. The incubated proteins were then washed and immunoblotted using anti-His or GST 493 antibodies. 
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